Want to see JP:4595 full AI Analyst Report?

Mizuho Medy Co., Ltd. (4595) Price & Analysis

0 Followers

4595 Stock Chart & Stats

¥1753.00

¥40.00(2.73%)

At close: Jan 08 4:00 PM EST

¥1753.00

¥40.00(2.73%)

Day’s Range― - ―

52-Week Range¥1,418.00 - ¥1,930.00

Previous CloseN/A

Volume223.50K

Average Volume (3M)64.11K

Market Cap

¥31.83B

Enterprise Value¥21.90K

Total Cash (Recent Filing)¥12.54B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)9.8

Beta0.41

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield5.97%

Share Statistics

EPS (TTM)170.57

Shares Outstanding19,051,200

10 Day Avg. Volume72,640

30 Day Avg. Volume64,113

Financial Highlights & Ratios

PEG Ratio-1.03

Price to Book (P/B)1.74

Price to Sales (P/S)2.88

P/FCF Ratio19.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)169.6

Revenue Forecast (FY)¥11.40B

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt provides durable financial flexibility and very low solvency risk, allowing the company to fund R&D, dividends or opportunistic M&A from internal resources. This structural strength supports resilience through industry cycles and reduces refinancing risk.

High Net MarginsA sustained net margin near 30% indicates structural operating efficiency or pricing power in its specialty/generic drug operations. High margins create an ongoing buffer to absorb cost shocks, support dividend capacity, and finance reinvestment without depending on external capital.

Consistent Positive Free Cash FlowConsistent positive free cash flow and close FCF-to-income conversion historically show reliable cash generation. Durable cash conversion underpins sustained capital returns, internal investment capacity and lowers reliance on debt, reinforcing long-term financial flexibility.

Bears Say

Weaker Cash Conversion In 2025The 2025 decline in operating cash flow and weaker conversion versus reported earnings signals increased cash volatility. If this persists it can constrain funding for dividends, capex and product investment, forcing reliance on balance sheet reserves or external financing.

Normalized Profitability; Falling ROEROE and margins retreating from 2021–2022 peaks indicates profitability has normalized. This reduces earnings leverage and limits upside from margin expansion, suggesting future returns may be more muted without new products or efficiency gains.

Choppy Revenue GrowthA choppy, only modestly growing top line implies limited organic growth momentum. Persistent revenue variability restrains long-term EPS growth and increases dependence on new product launches, pricing or market share gains to sustainably improve financial performance.

4595 FAQ

What was Mizuho Medy Co., Ltd.’s price range in the past 12 months?

Mizuho Medy Co., Ltd. lowest stock price was ¥1418.00 and its highest was ¥1930.00 in the past 12 months.

What is Mizuho Medy Co., Ltd.’s market cap?

Mizuho Medy Co., Ltd.’s market cap is ¥31.83B.

When is Mizuho Medy Co., Ltd.’s upcoming earnings report date?

Mizuho Medy Co., Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 13 days.

How were Mizuho Medy Co., Ltd.’s earnings last quarter?

Mizuho Medy Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥31.57 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Mizuho Medy Co., Ltd. overvalued?

According to Wall Street analysts Mizuho Medy Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mizuho Medy Co., Ltd. pay dividends?

Mizuho Medy Co., Ltd. pays a Semiannually dividend of ¥50 which represents an annual dividend yield of 5.97%. See more information on Mizuho Medy Co., Ltd. dividends here

What is Mizuho Medy Co., Ltd.’s EPS estimate?

Mizuho Medy Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mizuho Medy Co., Ltd. have?

Mizuho Medy Co., Ltd. has 19,051,200 shares outstanding.

What happened to Mizuho Medy Co., Ltd.’s price movement after its last earnings report?

Mizuho Medy Co., Ltd. reported an EPS of ¥31.57 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.231%.

Which hedge fund is a major shareholder of Mizuho Medy Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4595

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mizuho Medy Co., Ltd.

Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.